Alessia Argirò, Mattia Zampieri, Lorenzo-Lupo Dei, Cecilia Ferrantini, Alberto Marchi, Alessia Tomberli, Katia Baldini, Francesco Cappelli, Silvia Favilli, Silvia Passantino, Chiara Zocchi, Luigi Tassetti, Martina Gabriele, Niccolò Maurizi, Niccolò Marchionni, Raffaele Coppini, Iacopo Olivotto
OBJECTIVES: We assessed the efficacy and safety of ranolazine in real-world patients with hypertrophic cardiomyopathy (HCM). BACKGROUND: Ranolazine is an anti-anginal drug that inhibits the late phase of the inward sodium current. In a small prospective trial, ranolazine reduced the arrhythmic burden and improved biomarker profile in HCM patients. However, systematic reports reflecting real-world use in this setting are lacking. METHODS: Changes in clinical and instrumental features, symptoms and arrhythmic burden were evaluated in 119 patients with HCM before and during treatment with ranolazine at a national referral centre for HCM...
January 1, 2023: International Journal of Cardiology